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Abstract: A life-long dietary intervention can affect the substrates’ availability for gut fermentation 
in metabolic diseases such as the glycogen-storage diseases (GSD). Besides drug consumption, the 
main treatment of types GSD-Ia and Ib to prevent metabolic complications is a specific diet with 
definite nutrient intakes. In order to evaluate how deeply this dietary treatment affects gut bacteria, 
we compared the gut microbiota of nine GSD-I subjects and 12 healthy controls (HC) through 16S 
rRNA gene sequencing; we assessed their dietary intake and nutrients, their microbial short chain 
fatty acids (SCFAs) via gas chromatography and their hematic values. Both alpha-diversity and 
phylogenetic analysis revealed a significant biodiversity reduction in the GSD group compared to 
the HC group, and highlighted profound differences of their gut microbiota. GSD subjects were 
characterized by an increase in the relative abundance of Enterobacteriaceae and Veillonellaceae 
families, while the beneficial genera Faecalibacterium and Oscillospira were significantly reduced. 
SCFA quantification revealed a significant increase of fecal acetate and propionate in GSD subjects, 
but with a beneficial role probably reduced due to unbalanced bacterial interactions; nutritional 
values correlated to bacterial genera were significantly different between experimental groups, with 
nearly opposite cohort trends. 
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1. Introduction 
The evidence of interplay between intestinal commensal bacteria and host physiological 
functions has hugely grown over the last years, shedding new light on clinical research on 
pathological conditions [1]. Among them, inherited metabolic disorders have been shown to be 
related to gut microbiota composition [2], possibly for the crucial role that diet plays both in patient 
treatment and in microbial metabolite production. Here, we present our study involving patients 
affected by glycogen storage diseases (GSD) following the vitally specific diet. 
GSD are a group of hereditary metabolic disorders caused by the deficiency of one of the 
enzymes involved in glycogen metabolism. Glycogen is primarily stored in liver and muscle, and 
disorders of glycogen degradation may affect both tissues [3,4]. GSD types, grouped by the enzyme 
deficiency, were numbered as they were discovered, classifying them from GSD type I (von Gierke 
disease) to GSD type XI [5,6]. The present study focused our research on GSD-I, one of the most 
common types of glycogen storage diseases. 
GSD-I results in a defect in the glucose-6-phosphatase system, which is required for the 
hydrolysis of glucose-6-phosphate into glucose and inorganic phosphate [7,8], impairing free glucose 
availability during fasting and glucose homeostasis with consequent hypoglycemia. The clinical 
onset of GSD-I usually occurs in the first year of life, during complementary feeding, with symptoms 
related to severe fasting hypoglycemia, hepatomegaly, failure to thrive and growth retardation. The 
overall annual incidence is about 1 to 100,000 subjects [9,10]. 
Two main subtypes of GSD-I are recognized: type Ia (GSD-Ia), due to a defect of the catalytic 
subunit glucose-6-phosphatase-α in the endoplasmic reticulum, and responsible for 80% of cases of 
GSD-I [3], and type Ib (GSD-Ib), due to a defect of the glucose-6-phosphate translocase, the 
transporter for the entrance of glucose-6-phosphate into the endoplasmic reticulum [9]. Patients with 
GSD-Ib may be clinically and metabolically identical to those with GSD-Ia (showing typical physical 
findings, including protuberant abdomen, truncal obesity, doll-like faces, short stature and 
hypotrophic muscles [6]), but in addition, most patients with GSD-Ib develop neutropenia and 
neutrophil dysfunction that predispose them to severe infections and to inflammatory bowel disease 
(IBD) [11,12]. Although the development of IBD is associated to GSD-Ib, few cases of IBD were 
recently reported in GSD-Ia [13,14]. Dietary treatment is the cornerstone of GSD-I therapy, and it 
starts at diagnosis and is life-long. This regimen is characterized by small frequent meals high in 
complex carbohydrates (preferably with high fiber content) distributed over 24 h [15], including the 
night, and/or continuous feeding through nasogastric tube [16]. Thus, over the total amount of daily 
energy intake, the carbohydrate consumption is 60–70%, while 10–15% of calories are derived from 
proteins and the remaining calories from fat [17,18]. Raw cornstarch is typically introduced between 
6 months and 1 year of age [15], since its slow digestion can provide a steady intestinal release of 
glucose, maintaining more stable glucose levels over a longer period of time [19]. The restriction in 
sugar consumption is also crucial in the GSD-I diet, since fructose and galactose are metabolized to 
glucose-6-phosphate and can further contribute to the abnormal biochemical profile; in particular, to 
hyperlactacidemia [17,19]. 
The primary aim of the dietary treatment is not only avoiding hypoglycemia, but also achieving 
a good metabolic control [20], minimizing the secondary metabolic derangements and reducing long-
term complications. In order to prevent or treat some clinical conditions (proteinuria, osteoporosis) 
or biochemical abnormalities (hyperuricemia, hyperlipidemia), patients also take 
medications/supplementations such as an ACE inhibitor, allopurinol, fibrate, oil fish, calcium and 
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vitamin D3 [16]. GSD-Ib patients also assume granulocyte colony-stimulating factor (G-CSF) and 
anti-inflammatory drugs to treat neutropenia and IBD, respectively. 
Since nutritional intake is one of the most relevant factors influencing the gut microbiota’s 
composition [21], it is reasonable to expect that such a peculiar diet, along with the daily 
supplementations, could impact substrates’ availability for microbial fermentation, affecting the 
production of metabolites; in particular, short chain fatty acids (SCFAs). SCFAs, mainly represented 
by acetate, propionate and butyrate, are the end products of microbial fermentation in the 
gastrointestinal tract [22]. Their production is heavily influenced by bacterial cross-feeding 
interactions, in which acetate and other small molecules (i.e., lactate and succinate) act as substrates 
to produce butyrate and propionate, respectively [23]. SCFAs are suggested to be involved in the 
maintenance of the gut barrier function and in the promotion of gut homeostasis [24]. To date, there 
is no information about gut bacterial metabolite production and consumption regarding GSD 
microbiota.  
The aim of our study was thus to compare dietary macronutrient intake, gut microbial 
biodiversity and microbial metabolite production in patients with GSD-Ia/Ib and healthy subjects, in 
order to better evaluate and characterize diet or disease-related microbiome differences. 
2. Results 
2.1. Cohort Description 
Overall mean BMI values for the enrolled subjects were 26.8 ± 4.8 for GSD patients and 21.6 ± 2.9 
for healthy controls (HC) (p = 0.0176). Within the entire dataset, 3/21 resulted obese (3/9 GSD, 0/12 
HC), 4/21 overweight (3/9 GSD, 1 of which <18 years; 1/12 HC), 14/21 normal weight (3/9 GSD, 11/12 
HC).  
All GSD patients were taking drugs to prevent disease-related comorbidities. The reported 
medications/supplementations were: allopurinol (Ia = 3/4; Ib= 5/5), antihypertensive drugs (Ia = 1/4; 
Ib = 4/5), triglyceride lower-drugs (Ia = 1/4; Ib = 2/5), salicylates (Ia = 0/4; Ib = 2/5), granulocyte-colony 
stimulating factor (Ia = 0/4; Ib = 3/5) and multivitamin and calcium with vitamin D (Ia = 4/4; Ib = 5/5). 
Three GSD-Ib patients were reported to be neutropenic and to have IBD. 
Fasting blood samples of GSD patients were analyzed for total cholesterol, triglycerides, insulin, 
glucose, uric acid, liver enzymes and lactate (Supplementary Table S1). GSD patients showed slightly 
increased alanine aminotransferase (ALT, mean ± SD: 54.1 ± 43.44 U/L) and aspartate 
aminotransferase (AST, 42.5 ± 23.8 U/L) values compared to physiological levels (0–35 U/L). In 
particular, GSD-Ia showed higher values in both parameters (54.5 ± 28.3 U/L and 67.7 ± 47.1 U/L, 
respectively). GSD-Ia patients showed higher values of both total cholesterol and triglycerides (265.5 
± 152.2 mg/dL) and 422.5 ± 241.6 mg/dL, respectively), compared to normal levels (< 200 mg/dl and < 
150 mg/dl, respectively). Serum lactate was also increased in GSD-Ia patients (3.8 ± 1.9 mmol/L) 
compared to normal levels (0.7–1.15 mmol/L). 
2.2. Dietary Assessment 
The daily energy intakes and the diet macronutrient compositions of enrolled subjects are 
reported in Table 1. 
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Table 1. Nutritional values of the two enrolled groups. 
Nutritional variable 
HC 
Mean ± SD 
GSD 
Mean ± SD 
p-Value 
Energy Intake 
kcals 
 
1907 ± 603 
  
2420 ± 549 
  
0.0468 
  
* 
Proteins 
g 
% energy 
  
74.67 ± 22.92 
16.70 ± 3.77 
  
83.06 ± 20.56 
13.80 ± 2.20 
  
0.3824 
0.0815 
  
Lipids 
g 
% energy 
  
77.96 ± 47.06 
36.58 ± 10.65 
  
62.35 ± 15.47 
23.40 ± 3.26 
  
0.7021 
0.0013 
  
 
** 
Carbohydrates 
g 
% energy 
Sugars 
g 
% energy 
  
216.19 ± 54.55 
46.28 ± 9.01 
 
58.56 ± 25.44 
11.98 ± 4.74 
  
390.03 ± 97.78 
60.22 ± 4.54 
 
23.75 ± 9.11 
3.56 ± 1.06 
  
0.0007 
<0.0001 
 
0.0013 
<0.0001 
  
*** 
**** 
 
** 
**** 
Fiber 
overall, g 
overall, g/1000 kcal 
insoluble fiber, g 
soluble fiber, g 
  
15.44 ± 4.80 
8.58 ± 2.16 
6.43 ± 4.44 
2.01 ± 1.35 
  
21.01 ± 4.37 
9.10 ± 2.72 
9.59 ± 4.43 
3.57 ± 1.23 
  
0.0148 
0.7021 
0.1285 
0.0227 
  
* 
 
 
* 
Values are expressed as means (with standard deviations). Significant differences are indicated by * 
(p-value < 0.05), ** (p-value < 0.01), *** (p-value < 0.001) and **** (p-value < 0.0001), Mann–Whitney 
test. 
Compared to HC, GSD group showed a significantly higher daily energy (p = 0.0468) and 
carbohydrate intakes (both grams and % total energy, p = 0.002), but a lower lipid intake (% of total 
energy, p = 0.0013) was observed. No significant differences were observed for proteins. As expected 
from the dietary recommendations, sugar consumption was reduced in the GSD group (p = 0.0013), 
whereas the starch intake was higher in GSD (mean ± SD: 110.27 g ± 44.80) compared to HC (180.94 
g ± 62.81) (p = 0.004). Total fiber intake (p = 0.0148) and soluble fiber intake (p = 0.0227) were higher in 
GSD patients, whereas no significant differences were detected for the insoluble fraction. 
2.3. Microbiota Profiling 
To avoid biases related to uneven sequencing depth (raw reads ranging from 56,150 reads to 
350,680), samples were subsampled to 50,000 reads each by random picking. After quality filtering 
processes, we obtained a mean count of 40,988.261 reads per sample (total count of Operational 
Taxonomic Units (OTUs) for the entire dataset, average 1654 OTUs per sample). 
As shown in Figure 1A, alpha-diversity showed a significant lower biodiversity within GSD 
subjects for each metric used (chao1, p = 0.02; observed species, p = 0.02; Shannon, p = 0.002; Faith’s 
phylogenetic diversity, p = 0.03).  
A clear difference among HC and GSD subjects was highlighted in beta-diversity as well (Figure 
1B). Both unweighted and weighted Unifrac distances revealed a significant separation between 
groups (respectively, p = 0.004 and p = 0.01).  
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Figure 1. Biodiversity and phylogenetic analysis between cohorts. (A) Alpha-diversity indexes are 
reported for healthy control (HC) (blue) and glycogen storage disease (GSD) (red) subjects for chao1, 
observed species, Shannon diversity and Faith’s phylogenetic metrics. Diversity among groups is 
statistically significant for all metrics. (B) Beta-diversity analysis represented by PCoA graphs of 
weighted and unweighted UniFrac distance between HC (blue) and GSD (red) subjects. The ellipses 
of mean standard error (SEM)-based data confidence are reported. Microbial communities are 
statistically different for both distances (adonis test: unweighted p = 0.004; weighted p = 0.01). 
Percentage variance accounting for the first, second and third principal components is shown along 
the axis. To highlight possible differences related to GSD type, a color scheme was further applied to 
the GSD group: GSD-Ia (orange), GSD-Ib (red), GSD-Ib with inflammatory bowel disease (IBD) (red 
+ cross). 
2.3.1. Taxonomic Characterization 
We found several significant differences in taxas’ relative abundances among the two groups 
across all phylogenetic levels.  
At the phylum level (Figure 2A), differences were found in the relative abundance of Firmicutes 
(GSD 55.9% vs. HC 70%, although not significant) and Proteobacteria (GSD 17% vs. HC 1.4%, p = 
0.001). Several dominant families were also significantly diverse in the two cohorts: Ruminococcaceae 
(p = 0.002), Veillonellaceae (p = 0.030) and Enterobacteriaceae (p = 0.006) (Figure 2B). Note, while 
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Ruminococcaceae was more abundant among controls (40.3% vs. 15% GSD), both Veillonellaceae and 
Enterobacteriaceae were much higher among GSD patients (respectively, 13.8% and 16.3% compared 
to 4.7% and 1.1% among HC). As shown in Figure 2C, at the genus level GSD patients were severely 
and significantly depleted in Ruminococcus (1.4% vs. 7.2% in HC; p = 0.0173), Faecalibacterium (7.4% 
vs. 19.6%; p = 0.0209) and Oscillospira (0.6% vs. 3.3%; p = 0.0020). In total, 1596 OTUs out of were 
classified as Enterobacteriaceae at the family level, and 792 of them were annotated as Escherichia coli. 
GSD patients were found significantly increased in Escherichia coli compared to HC (10% vs. 0.93%, p 
= 0.0077). 
 
Figure 2. Taxonomic characterization. Stacked bar charts of taxonomy relative abundances at (A) 
phylum, (B) family and (C) genus levels for healthy controls (HC) and GSD patients. Only phyla, 
families and genera present at relative abundances >1% in at least 20% subjects (i.e.: ≥ 4 samples) are 
reported. Remaining taxa are grouped in the “Other” category for each level. 
All relative abundances and significant p values are reported in Table 2.  
Table 2. Taxonomic relative abundance at the genus level. 
Genus 
Average Relative Abundance 
p-Value 
HC GSD 
Bacteroides 18.83 14.43 0.2410 
Faecalibacterium 19.61 7.44 0.0209* 
Unclassified Ruminococcaceae 8.94 5.27 0.0700 
Ruminococcus 7.25 1.42 0.0173* 
Escherichia 0.99 10.01 0.0077** 
Unclassified Clostridiales 6.87 0.29 0.0025** 
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Akkermansia 1.63 6.26 0.2323 
Unclassified Lachnospiraceae 4.48 1.41 0.0428* 
Roseburia 3.27 1.50 0.0428* 
Dialister 3.57 1.64 0.0360* 
Coprococcus 2.43 2.80 0.4138 
Oscillospira 3.35 0.64 0.0020** 
Unclassified Rikenellaceae 2.35 1.87 0.1657 
Veillonella 0.41 4.73 0.1265 
Clostridium 0.76 3.94 0.4996 
Streptococcus 0.51 4.16 0.1886 
Blautia 1.40 1.83 0.4996 
SMB53 0.29 3.05 0.0360* 
Parabacteroides 1.07 0.84 0.1658 
Phascolarctobacterium 0.51 1.58 0.4946 
Megamonas 0.00 5.64 0.0092** 
Citrobacter 0.07 5.33 0.3609 
Bifidobacterium 0.23 0.70 0.7754 
Other genera 10.68 13.41 -- 
The main genera in GSD patients and healthy controls, selected for <1% abundance in at least one of 
the two groups, are reported. All bacterial taxa present at less than 1% relative abundance were 
grouped into the “Other genera” classification. Significant differences are indicated by * (p-value < 
0.05) and ** (p-value < 0.01). 
2.3.2. Fecal Microbial Metabolites 
Gas-chromatography analysis revealed an increased production of total fecal short chain fatty 
acid (SCFA) in GSD group (p = 0.0159). In particular, the concentration of acetate and propionate were 
higher in patients (p = 0.031 and p = 0.038, respectively), whereas the concentration of butyrate was 
similar in the two groups (p = 0.8381). No significant differences were found for the branched-chain 
fatty acids iso-valerate and iso-butyrate between the two groups (Supplementary Table S2). 
2.3.3. Functional Prediction 
At a broad functional level (level 2 KEGG), the functional analysis predicted an enrichment in 
genes encoding enzymes for amino acid metabolism (p = 0.0094); in particular, tryptophan (p = 0.017), 
glutathione (p = 0.009) and beta-alanine (p = 0.0004); and for lipid metabolism, alpha-linolenic acid 
especially (p = 0.025). Intriguingly and counterintuitively, the starch and sucrose metabolism 
pathways were significantly reduced in GSD subjects (respectively, p = 0.026).  
Metabolites 2020, 10, 133 8 of 17 
 
2.4. Relationship between Microbial Population, Metabolite Content and Diet 
2.4.1. Gut Microbiota and Fecal Microbial Metabolites 
A correlation analysis was applied to investigate possible associations between SCFA 
concentration and bacterial taxa, as shown in Figure 3.  
 
Figure 3. Correlation between SCFA values and bacterial genera. Heatmap showing Spearman’s 
correlations between the most abundant microbial genera and SCFA concentrations. Red tiles indicate 
a positive correlation, blue tiles a negative one for both HC and GSD groups. 
The obtained data revealed positive correlations between the Blautia, Dorea and 
Phascolarctobacterium genera, increased in GSD patients, and propionate concentration (R = 0.61, R = 
0.82, R = 0.71, respectively). On the other side, we observed Faecalibacterium and Oscillospira 
(significantly decreased in GSD subjects) to be negatively related to acetate concentrations (R = −0.47, 
R = −0.51).  
2.4.2. Impact of Diet on Microbial Taxa Relative Abundance 
Correlations of nutritional parameters to bacteria abundances revealed several divergent 
relationships between the two cohorts, as shown in the Figure 4.  
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Figure 4. Correlations between nutritional and taxonomic values. Bacterial genera are reported in the 
same order of relative abundance as in Table 2, in correlation with the nutritional values shown in 
Table 1 according to Spearman’s correlation. Red tiles indicate a positive correlation, blue tiles a 
negative one for both HC and GSD groups. 
Fiber intake showed a strong positive correlation to Odoribacter and Parabacteroides genera (total 
fibers: R = 0.79, R = 0.78; insoluble fibers: R = 0.79, R = 0.81) only in GSD patients, whereas a milder, 
opposite trend characterized the HC group. In GSD patients, starch intake positively correlated with 
Veillonella, Citrobacter and Akkermansia genera (R = 0.299, R = 0.334 and R = 0.406, respectively) and 
negatively with Coprococcus and Clostridium genera (R = −0.826 and R = −0.823, respectively). The latter 
two genera, in particular, showed an opposite trend with nutritional values between the two groups 
(correlated positively to HC and negatively to GSD patients). 
3. Discussion 
Our study investigated the impact of the life-long cornstarch-rich diet characterizing the 
treatment of GSD patients by integrating gut microbiota, microbial metabolites and nutritional data. 
The identification of bacterial metabolism is crucial for the understanding of a possible microbial role 
in metabolic diseases. For this reason, we highlighted the importance of short chain fatty acids in gut 
microbiota characterization as bacteria cooperate and feed one on another’s products (cross-feeding). 
To our knowledge, this is the first study evaluating the impact of the cornerstone diet of GSD-I on 
gut microbial cross-feeding and metabolites production.  
During the last decade, a healthy gut microbiota has been typically characterized by members 
of the phyla Bacteroidetes and Firmicutes, and their genera are believed to be the main responsible 
bacteria for positive biodiversity in the human gut [25], as their balanced abundances and metabolite 
productions protect the intestinal trait, help digestion and modulate the host innate immune system 
[26]. In agreement with Colonetti and coworkers [27] that have analyzed the gut microbiota of 
different types of GSDs, we found a strong reduction in intestinal microbiota richness and diversity 
compared with healthy controls and a dramatic increase in the phylum Proteobacteria. 
Though the GSD diet is enriched in starch and fibers, usually considered good substrates 
promoting beneficial microbes’ growth, Proteobacteria, in particular, the Enterobacteriaceae family, 
have been suggested to exert pro-inflammatory activity both locally, at the gastrointestinal mucosa 
level, and systemically [28]. In turn, an inflamed gut seems to constitute a commending environment 
for proliferation of Enterobacteriaceae bacteria [29], and it is also characterized by a depletion of 
obligate anaerobes, typically recognized as fiber-degrading bacteria [30]. Although GSD-Ib are 
genetically at risk of intestinal bowel inflammation [16] and three GSD-Ib patients in our dataset were 
indeed affected, the enrichment in the relative abundance of Escherichia coli spanned both type Ia and 
Ib patients. This data could account for the increased abundance in genes for glutathione metabolism 
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in GSD, since E. coli accumulates the tripeptide in order to protect itself from chemical and 
environmental stress [31]. Despite the high amount of starch in GSD diet, we predicted a reduction 
of the starch and sucrose metabolism genes, which could be linked to a possible intestinal imbalance 
caused by both the Proteobacteria’s abnormal abundance and the decrease of obligate anaerobes. 
Within an inflamed environment, the availability of simple sugars could be altered, and bacteria 
forced to exploit other nutritional sources such as amino acids. Enterobacteriaceae, as seen for the strain 
E. coli LF82, associated to Crohn’s disease, seem to be able to catabolize dietary L-serine in order to 
maximize their growth [32]. On the other hand, GSD group showed increased amino-acid metabolism 
genes compared to HC, suggesting that Enterobacteriaceae may contribute to the increment of this 
pathway. Other taxonomic indicators of inflammatory status in GSD patients were the enrichment of 
the Blautia genus, known to stimulate cytokines secretion by host cells [33], and the significant 
depletion of Oscillospira and Faecalibacterium species. Data about the observed relative abundance of 
Faecalibacterium spp. and Escherichia spp. are in agreement to what Grabherr and colleagues [34] have 
observed in non-alcoholic steatohepatitis (NASH). Of note, both GSD and NASH are affected by liver 
damage, and the elevated ALT values found in our patients’ blood samples confirms this similarity. 
The depletion in Faecalibacterium and Oscillospira spp. is a hallmark for patients gut microbiota 
alteration, as these genera are considered as biomarkers of intestinal and host wellness. 
Faecalibacterium spp. has the ability to produce anti-inflammatory molecules [35], and also a specific 
protein able to block NF-κB pathway [36]. The genus Oscillospira has been found to be constantly 
reduced in inflammatory diseases as well as Faecalibacterium spp. with decreased abundances in 
Crohn’s disease, both colonic and ileal [37], and in pediatric nonalcoholic steatohepatitis [38]. 
Moreover, several studies associated Oscillospira spp. to lower BMI and leanness-promoting bacteria 
such as Christensenella minuta [39,40]. Our data confirmed these observations, since we observed a 
higher prevalence of obesity/overweight in GSD cohort compared to HC, and a depletion of 
Christensenella spp. in the patients’ gut. Colonetti and coworkers [27] did not observe changes in 
Faecalibacterium and Oscillospira relative abundances in their dataset, and found Blautia spp., enriched 
in our cohort, to be depleted in GSD patients. These differences could be ascribable to the multiplicity 
of GSDs (type Ia/Ib, III, IX vs. type Ia/Ib), the use of antibiotics before sampling (10/24 subjects vs. 
0/9), the sequencing method used (Ion Torrent vs. Illumina MiSeq) and the database used for OTU 
processing (SILVA vs. Greengenes). 
Byndloss and coworkers demonstrated, in vitro and in vivo, the existence of a vicious cycle 
encompassing the depletion of butyrate-producing microbes and the increase of Enterobacteriaceae in 
the gut microbiota [41]. Indeed, antibiotic-driven reduction of Lachnospiraceae and Ruminococcaceae, 
major butyrate producers, promotes the use of glucose instead of butyrate by colonocyte. This 
metabolic switch-anaerobic glycolysis-fails to suppress host-derived nitrate and oxygen production, 
promoting the growth of facultative anaerobes such as Enterobacteriaceae. On the other hand, the 
decrease of butyrate downregulates Tregs and epithelial PPAR-γsignaling further promotes the 
epithelial dysfunction. 
We conducted this research considering that the bioavailability of substrates introduced with 
the diet drives the gut’s microbial composition, and consequently, alterations in intestinal microbiota 
can lead to a different production of microbial metabolites.  
For instance, the important role Faecalibacterium spp. plays in gut microbiota is directly linked to 
the production of butyrate, the main energy source for enterocytes with a protective role in colorectal 
cancer and in IBD [42]. On the other hand, the decrease of these bacteria in GSD gut microbiota did 
not result in a reduction of fecal butyrate concentrations, found in similar amounts in GSD and 
controls, whereas it could have caused the higher acetate quantities, since this fatty acid has been less 
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used in fermentation reactions. The negative correlation we found between Faecalibacterium spp. and 
acetate concentrations leads in that direction.  
Compared to HC, GSD patients were observed to have a higher concentration of total SCFAs; in 
particular, acetate and propionate. Those SCFAs have key-roles in gut microbial composition: for 
instance, acetate production is strongly regulated by the cross-feeding within the gut microbial 
community. Indeed, Samuel and Gordon [43] underlined that the co-colonization with Bacteroides 
thetaiotaomicron/Methanobrevibacter smithii increased serum acetate levels compared to B. 
thetaiotaomicron alone in gnotobiotic mice. 
The higher acetate concentration can be ascribed to several intestinal bacteria found to be more 
abundant in GSD gut microbiota, including Akkermansia muciniphila and Bifidobacterium spp., which 
produce acetate by fermenting acetogenic fibers, and to a lesser extent, protein-derived peptides [44]. 
As well as acetate, propionate seems to exert protective and anti-inflammatory activities in IBD, 
ameliorating the intestinal mucosa lesion [45]. The higher propionate concentration is in agreement 
with the enrichment in Veillonellaceae family among GSD patients [46]; the genus Veillonella was found 
positively related to starch intake in patients, probably because of their peculiar diet. GSD patients 
were also enriched in Megasphaera genus, which is able to produce propionate from lactate through 
acrylate pathway [46]. 
Considering the opposite trends observed between GSD patients and HC, our results indicate 
that GSD patients have an ongoing alteration in gut microbial community cross-fed by increased pro-
inflammatory genera and decreased beneficial bacteria. The specific dietary treatment does not seem 
to help the composition of gut microbial community in patients, as the anti-inflammatory genera 
were depleted and not sufficient to counterbalance the dysbiosis. Probiotics supplementation could 
offer another way to improve and ameliorate the gut microbial population in GSD patients. Carnero-
Gregorio and colleagues [14] recently reported a prospective case study pointing toward this 
direction: by testing a probiotic mixture in a patient with GSD-Ia and Crohn-like IBD, the authors 
observed a reduced number of bowel episodes and an improvement the patient’s quality of life. 
Moreover, they found a reduction in Enterobacteriaceae relative abundance after the probiotic 
treatment. 
Since patients are commonly taking multiple drugs to cope with the variety of comorbidities 
characterizing glycogen storage diseases, we tried to evaluate their possible impacts on the microbial 
community. Indeed, multi-drug usage has been reported to impact microbial composition and 
richness, but it is difficult to assess whether the observed alterations are caused by the high number 
of drugs or by the disease itself, forcing the patient to take all these medications [47]. Whereas few 
drugs seem to have a direct effect on the microbiota, i.e., metformin or proton pump inhibitors, the 
association of multiple compounds is not clearly associated to the depletion or enrichment of specific 
taxa. All the patients but one were taking allopurinol, a common urate-reducing drug. In a rodent 
model of hyperuricaemia, its use was associated with an increase in the relative abundance of 
Bifidobacterium spp. [48]. In our GSD patients, we did observe a slight increase in this genus, but this 
observation should be confirmed in a bigger cohort. 
In conclusion, we believe that our study could pave the way for further investigations of the 
intestinal bacterial community in GSD type Ia and Ib patients and in similar metabolic syndromes. In 
the frame of glycogen storage diseases, studies evaluating gut microbiota differences in large 
multicentric cohorts are needed to expand our results obtained by a cohort limited by the rarity of 
the disease, albeit homogeneous. Nevertheless, our study showed how profoundly gut microbiota 
can be modulated by a life-long diet. Importantly, future studies should aim at clarifying whether the 
observed changes are driven by nutritional parameters only or also by the disease itself. 
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4. Materials and Methods  
4.1. Subject Recruitment and Sampling 
For this study, 9 GSD type I patients (Ia = 4, Ib = 5) and 12 healthy controls (HC) were enrolled 
from January 2018 to June 2018. The dataset consisted of 21 subjects, gender and age matched between 
groups. Mean age of GSD patients was 27.7 ± 12.5 years (6 males and 3 females), while mean age of 
HC was 24.7 ± 7.9 years (9 males and 3 females). Despite only six subjects, three GSD and three HC, 
being of pediatric age, all the enrolled subjects in the study were followed by the Pediatric 
Department of San Paolo Hospital, reference center for metabolic diseases in Milan (Italy). For both 
patients and controls, inclusion criteria were: gestational age 37–42 week inclusive, birth weight ≥ 
2500 g and single birth; exclusion criteria were: treatments with antibiotic and/or probiotic/prebiotic 
assumption during the previous 3 months. 
Specific GSD inclusion criteria were: disease clinical onset during childhood and the diagnosis 
confirmed by liver biopsy (% hepatic glycogen and glucose-6-phosphatase enzymatic activity assay); 
dosage of deoxyglucose transport in polymorphonuclear neutrophils (only in patients with GSD Ib) 
and/or molecular analysis of GSD; to be on treatment with CS; not to have type I/II diabetes. 
Stool samples, stored at −80 °C until use, were collected for each subject. Pediatricians performed 
anthropometric measurements (height, weight) and body mass index was calculated; the nutritional 
weight status was evaluated through the WHO classification of underweight, overweight and obese 
adult for patients >18 years [49], while for patients ≤ 18 years standard scores (z-scores) of BMI were 
calculated and evaluated using WHO reference standard [50]. 
Furthermore, a 24-h food recall was provided by patients themselves or by parents to collect 
dietary data. Dietary food records were processed by dieticians in order to calculate the average 
amounts of energy and nutrient intake (carbohydrates, soluble glucids, starch, soluble and insoluble 
fibers, lipids, proteins) using commercially available software (MetaDietaR, Software version 3.1, 
ME.TE.DA S.r.l., San Benedetto del Tronto, Italy). For each subject, the use of drugs was also 
evaluated. 
In addition, in conjunction with the stool collection, we collected biochemical data of GSD 
patients from their routine check-up. The metabolic parameters evaluated were: glycemia, insulin 
(with HOMA-IR, HOMAβ, QUICKI and Tyg-Index calculation), total cholesterol, triglycerides, uric 
acid, lactate and transaminases. The HOMA-IR (homeostasis model assessment of insulin resistance) 
was calculated as follows: [basal blood glucose (mg/dl) × basal insulin (IU/mL)]/405; the QUICKI 
(quantitative insulin sensitivity index) was calculated as follows: 1/[log10 insulin (μUI/mL) + log10 
basal blood glucose (mg/dL)]; HOMAβ (Homeostatic Model Assessment of β-cell function) was 
calculated as follows: 20 × basal insulin (μUI/mL)/[basal blood glucose (mmol/L) -3.5] [51]; the Tyg-
index (triglycerides and glucose index) was calculated as follows: Log [triglycerides (mg/dL) × 
glycaemia (mg/dL)/2] [52]. 
The study was conducted at the Pediatric Department of San Paolo Hospital in Milan, with the 
previous approval by Ethics Committee of San Paolo Hospital in Milan (Comitato Etico Milano Area 
1, Protocol number 2017/ST/13749); written informed consent was obtained from each enrolled 
subject. 
4.2. Gut Microbial DNA Extraction and Sequencing 
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Fecal DNA extraction was performed using the Spin stool DNA kit (Stratec Molecular, Berlin, 
Germany), according to manufacturer’s instructions. For each sample, 25 ng of extracted DNA was 
used to construct the sequencing library. 
The V3–V4 hypervariable regions of the bacterial 16S rRNA gene were amplified with a two-
step barcoding approach according to the Illumina 16S Metagenomic Sequencing Library Preparation 
(Illumina, San Diego, CA, USA). Briefly, DNA samples were amplified with dual-index primers using 
a Nextera XT DNA Library Preparation Kit (Illumina) and library concentration and quantification 
were determined using a KAPA Library Quantification Kit (Kapa Biosystems, Woburn, MA, USA) 
and Agilent 2100 Bioanalyzer System (Agilent, Santa Clara, CA, USA), respectively. The libraries 
were pooled and sequenced with a MiSeq platform (Illumina) for 2 × 250 base paired-end reads and 
a total of 2.5 Gbases raw reads were obtained. 
4.3. Microbiota Profiling 
The obtained 16S rRNA gene paired sequences were merged using Pandaseq [53] (release 2.5). 
Reads were filtered by trimming stretches of 3 or more low-quality bases (quality < 3) and discarding 
the trimmed sequences whenever they were shorter than 75% of the original one. 
Bioinformatic analyses were conducted using the QIIME [54] pipeline (release 1.8.0), clustering 
filtered reads into Operational Taxonomic Unit (OTUs) at 97% identity level and discarding 
singletons as possible chimeras. Taxonomic assignment was performed via the RDP classifier [55] 
against the Greengenes database [56] (v 13_8). 
Alpha-diversity was computed using the chao1, number of OTUs, Shannon diversity and Faith’s 
phylogenetic diversity whole tree (PD whole tree) metrics through the QIIME pipeline; statistical 
evaluation among alpha-diversity indices was performed by a non-parametric Monte Carlo-based 
test, using 9999 random permutations. Weighted and unweighted UniFrac distances and Permanova 
(adonis function) in the R package vegan [57] (version 2.0–10) were used to compare the microbial 
community structure of GSD and HC subjects. A functional prediction of the bacterial metabolic 
pathways was performed using PICRUSt software [58] (version 1.0.1) and KEGG pathways database 
[59]. Differences in functional category profiles between breeds were assessed using Bray–Curtis 
distance among samples and “adonis” permutation-based test on the experimental labels. 
4.4. Fecal Short Chain Fatty Acids Measurement 
Fecal short chain fatty acids (SCFAs) quantification was performed by gas chromatography. 
Concentrations of acetic, propionic, iso-butyric, butyric and iso-valeric acids were assessed as 
previously described [60]. 
Briefly, analyses were performed using a Varian model 3400 CX Gas chromatograph fitted with 
FID detector, split/splitless injector and a SPB-1 capillary column (30 m × 0.32 mm ID, 0.25 μm film 
thickness; Supelco, Bellefonte, PA, USA). Quantification of the SCFAs was obtained through 
calibration curves of acetic, propionic, iso-butyric, butyric, and iso-valeric acid in concentrations 
between 0.25 and 10 mM (10 mM 2-ethylbutyric acid as internal standard). Results are expressed as 
mg/g of wet weight of feces. 
4.5. Statistical Analysis 
All comparisons were performed using MATLAB software (Natick, MA, USA; version 2008b). 
Comparisons of the two groups were performed using Student’s t-test for normally distributed 
variables and Wilcoxon test for non-normally distributed variables. For evaluating differences in 
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relative abundances of bacterial groups, a Mann–Whitney U-test was performed. Due to the small 
number of samples, no correction methods have been applied. 
Correlations between taxa and nutritional values and SCFA quantities were assessed through 
Spearman correlation and the associated linear regression model. p-values < 0.05 were considered as 
significant for each analysis. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Table S1: Blood 
biochemical parameters in GSD patients. Table S2: Fecal SCFA concentrations. Raw reads are available in NCBI 
Short Read Archive (SRA, http://www.ncbi.nlm.nih.gov/sra) under accession number PRJNA614988. 
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